Mao Changchuin, Near Richard, Shibad Varuna, Zhong Xuemei, Gao Wenda
Antagen Pharmaceuticals, Inc., Boston, MA 02118, USA.
Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA.
Antib Ther. 2020 Jul;3(3):157-162. doi: 10.1093/abt/tbaa014. Epub 2020 Jul 25.
Most pathogens establish infection through mucosa, where secretary IgA (sIgA) plays an "immune exclusion" role in humoral defense. Extravasation of intravenously administrated therapeutic IgG mainly relies on convection and/or FcRn-mediated transcytosis from circulation into interstitial space. Active transport of interstitial IgG further across epithelium into mucosa, like sIgA, is a much desired feature for the next generation of therapeutic antibodies, especially for anti-infection purposes. For the first time, we report the engineering of an IgA mimicry of IgG, with its Fc portion in fusion with the 18-aa tail piece (tp) of sIgA and the J chain, possessing sIgA's full binding activity towards Polymeric Immunoglobulin Receptor (pIgR) that mediates mucosa transcytosis. In a Diphtheria toxin receptor (DTR) knockin mouse model, i.v. injected anti-DT IgG(tp)J protected DTR+ cells from deletion upon DT injection. The compact design of IgG(tp)J opens new revenues for more effective therapeutic IgG mimicking some of the important biological functions of IgA.
大多数病原体通过黏膜建立感染,在黏膜处,分泌型IgA(sIgA)在体液防御中发挥“免疫排除”作用。静脉注射的治疗性IgG的外渗主要依赖对流和/或FcRn介导的从循环到间质空间的转胞吞作用。间质IgG进一步像sIgA一样主动转运穿过上皮进入黏膜,这是下一代治疗性抗体非常期望具备的特性,尤其是用于抗感染目的时。我们首次报道了一种IgG的IgA模拟物的工程改造,其Fc部分与sIgA的18个氨基酸的尾段(tp)和J链融合,具有sIgA对介导黏膜转胞吞作用的多聚免疫球蛋白受体(pIgR)的完全结合活性。在白喉毒素受体(DTR)敲入小鼠模型中,静脉注射抗DT IgG(tp)J可保护DTR+细胞在注射DT后不被清除。IgG(tp)J的紧凑设计为更有效地模拟IgA某些重要生物学功能的治疗性IgG开辟了新途径。